2052.6000 -22.30 (-1.07%)
NSE Aug 05, 2025 15:31 PM
Volume: 429.6K
 

2052.60
-1.07%
HDFC Securities
Maintain buy with a TP of Rs 800 (16x Dec-21E EPS + Rs 135/sh for pipeline). Glenmark reported broadly in-line numbers as revenues grew 16% YoY to Rs 25.6bn, and EBITDA came in at Rs 4.3bn with 17% margin. However, PAT at Rs 1.2bn was much lower than expectation owing to a Rs 1.3bn forex loss included in other income.
ICICI Securities Limited increased Sell price target of Glenmark Pharmaceuticals Ltd. to 1620.0 on 18 Jul, 2025.
More from Glenmark Pharmaceuticals Ltd.
Recommended